HDAC4 Protein is a protein involved in key cellular signaling pathways relevant to neurodegenerative diseases. This page provides comprehensive information about its structure, normal biological function, and role in disease pathogenesis.
HDAC4 Protein participates in critical cellular processes that, when dysregulated, contribute to neurodegeneration. Understanding this protein's function is essential for developing therapeutic interventions for Alzheimer's disease, Parkinson's disease, and related conditions.
| HDAC4 Protein | |
|---|---|
| Protein Name | HDAC4 |
| Gene | [HDAC4](/genes/hdac4) |
| UniProt ID | Q9Y5J8 |
| PDB Structure | 2VQJ, 5A2T, 6DRM |
| Molecular Weight | 119 kDa |
| Subcellular Localization | Nucleus, Cytoplasm (signal-dependent) |
| Protein Family | Class IIa histone deacetylases |
HDAC4 contains an N-terminal catalytic domain and a C-terminal regulatory region with conserved motifs. It has a nuclear localization signal (NLS) and nuclear export signal (NES), allowing nucleocytoplasmic shuttling. The catalytic domain deacetylates histone and non-histone substrates. HDAC4 interacts with various transcription factors and co-repressors.
HDAC4 is a class IIa histone deacetylase that regulates gene expression by removing acetyl groups from histone tails, promoting chromatin condensation and transcriptional repression. It shuttles between cytoplasm and nucleus in response to calcium, cAMP, and growth factor signaling. In neurons, HDAC4 regulates synaptic plasticity, memory formation, and neuronal survival through epigenetic regulation of gene expression programs.
HDAC4 is implicated in neurodegenerative diseases. In AD, HDAC4 nuclear localization and activity are altered, affecting genes involved in neuronal survival and synaptic function. HDAC4 contributes to memory deficits in AD models, and its inhibition improves cognitive function. In Huntington's disease, HDAC4 aggregates with mutant huntingtin.
HDAC4 inhibitors are being explored for neurodegenerative diseases. Vorinostat (SAHA) and other HDAC inhibitors show benefits in AD and HD models. More selective HDAC4 inhibitors are in development. Challenges include achieving brain penetration and isoform specificity.